Cargando…

PM401. NMDA-enhancing agents improve cognitive function of patients with schizophrenia

Detalles Bibliográficos
Autor principal:	Lane, Hsien-Yuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5616337/ http://dx.doi.org/10.1093/ijnp/pyw041.401

Ejemplares similares

40.1 INFLAMMATORY CYTOKINES ARE ELEVATED IN THE MIDBRAIN IN SCHIZOPHRENIA
por: Purves-Tyson, Tertia, et al.
Publicado: (2018)

PM368. Ketogenic diet normalises schizophrenia-like behaviours in acute and chronic NMDA-receptor hypofunction models
por: Kraeuter, Ann-Katrin, et al.
Publicado: (2016)

PM405. Sodium Benzoate Add-on Treatment for Refractory Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial
por: Lin, Chieh-Hsin, et al.
Publicado: (2016)

PM521. Relationship between Negative Symptoms and Social Cognition in Patient with Schizophrenia
por: Hyun, Jiewon, et al.
Publicado: (2016)

PM378. A reduced risk of severe hepatic outcome with paliperidone exposure in schizophrenia patients with viral hepatitis: a population-based retrospective cohort study
por: Chang, Chun-Hung, et al.
Publicado: (2016)

PM493. Interactions of tardive dyskinesia with cognitive function in patients with schizophrenia: worsening of working memory with clozapine treatment
por: Kim, Soo In, et al.
Publicado: (2016)

MED22/401: Hypertext Atlas For Pathology Education
por: Feit, J, et al.
Publicado: (1999)

PM441. Long term atypical antipsychotic treatment improves cognitive performance in schizophrenia but not surpassing conventional antipsychotic drugs effects.
por: Vera, Gabriel Selva, et al.
Publicado: (2016)

PM372. Functional change of serotonin 2C receptors in N-Methyl-D-aspartate (NMDA) receptor hypofunctional condition
por: Tsutsumi, Takahiro, et al.
Publicado: (2016)

PM541. Computational modeling of cognitive deficits from cortical circuit dysfunction associated with schizophrenia
por: Murray, John
Publicado: (2016)

PM505. Impaired glucose tolerance, symptoms and cognitive deficits in first-episode drug-naïve patients with schizophrenia
por: Zhang, Xiang-Yang, et al.
Publicado: (2016)

PM542. Cognitive control deficits in patients with schizophrenia, bipolar I disorder and unaffected first-degree relatives
por: Yun, Hyerim, et al.
Publicado: (2016)

PM461. Inflammation in schizophrenia: Imaging genetics
por: Hwang, Wu Jeong, et al.
Publicado: (2016)

PM394. The outcome of paliperidone palmitate in schizophrenia
por: Ju, Po-Chung
Publicado: (2016)

PM391. THE USE OF AMISULPRIDE IN TREATMENT OF PATIENTS WITH RESIDUAL SCHIZOPHRENIA
por: Janjic, Vladimir, et al.
Publicado: (2016)

PM367. Effect of cannabidiol on cognition in a maternal immune activation (poly IC) model of schizophrenia
por: Osborne, Ashleigh L., et al.
Publicado: (2016)

The complete idiot's guide to protecting your 401(k) and IRA
por: Lane, Jennifer, et al.
Publicado: (2009)

PM323. Cognitive function improvement in alcoholic dementia after 12 week memantine treatment
por: Kim, Yeonjin, et al.
Publicado: (2016)

PICK1 Genetic Variation and Cognitive Function in Patients with Schizophrenia
por: Chen, Yi-Ting, et al.
Publicado: (2017)

PM443. The ECT Augmenting Effects for Patients with Clozapine-Resistant Schizophrenia
por: Kim, Hye Sung, et al.
Publicado: (2016)

PM464. Effect of Anhedonia on Shopping Behavior in Schizophrenia
por: Kim, Min-Kyeong, et al.
Publicado: (2016)

PM432. Evaluation of the extrapyramidal side effects (EPS) liability of NMDA receptor glycine-binding site agonists
por: Ohno, Yukihiro, et al.
Publicado: (2016)

PM495. Neuropathology and functional analysis of schizophrenia associated variant in the MIR137 locus
por: Cairns, Murray, et al.
Publicado: (2016)

Antipsychotic treatment and cognitive function in patients with schizophrenia
por: Tumova, M. A., et al.
Publicado: (2023)

PM444. Effectiveness of Integrating Cognitive Remediation Program into Everyday Clinical Practice of Schizophrenia at Psychiatric Rehabilitation Settings
por: John, Alexander, et al.
Publicado: (2016)

PM468. Alterations of structural connectivity in patients with schizophrenia: a systematic review
por: Oh, Hye Rim, et al.
Publicado: (2016)

PM400. Differences in assessing insight into psychosis between clinicians and patients with schizophrenia
por: Kwak, Sook Young, et al.
Publicado: (2016)

PM407. Factors of Caregiver Burden and Quality of Life in Caregivers of Patients with Schizophrenia
por: Maeng, Seri
Publicado: (2016)

PM425. Relationship between suicidality and low self-esteem in patients with schizophrenia
por: Yoo, Taeyoung
Publicado: (2016)

PM358. Antidepressant Prescription pattern and Clinical Correlates for Schizophrenia
por: Kim, Jungwon, et al.
Publicado: (2016)

PM518. Medication Adherence in schizophrenia: Focus on therapeutic relationship
por: Chang, Jhin-Goo, et al.
Publicado: (2016)

401. Risk of Post-COVID Conditions Correlates with IL-6 Plasma Levels and Is Reduced by Early Antibody Therapy
por: Fukuta, Yuriko, et al.
Publicado: (2023)

PM388. Brain function measures of therapeutic effects of pharmacotherapy in schizophrenia: An fMRI study
por: Hasegawa, Sayaka, et al.
Publicado: (2016)

PM524. VEGF may have a neuroprotective role in the improvement of schizophrenia or in the treatment effects of antipsychotics
por: Kim, Yongku, et al.
Publicado: (2016)

Medications Used for Cognitive Enhancement in Patients With Schizophrenia, Bipolar Disorder, Alzheimer’s Disease, and Parkinson’s Disease
por: Hsu, Wen-Yu, et al.
Publicado: (2018)

P4.01. Omega-3 Fatty Acids Throughout the Pediatric Lifecycle
por: McClafferty, Hilary
Publicado: (2013)

PM439. Chronic effects of aripiprazole on the GSK3ß-dependent pathways, NMDA receptor and CREB1 in the rat brain
por: Pan, Bo, et al.
Publicado: (2016)

PM380. Treatment successful rate and efficacy of Paliperidone ER in patients with acute schizophrenia
por: Chen, Yi-hsing
Publicado: (2016)

PM393. Antipsychotic polypharmacy patterns and antipsychotic psychiatric medication adherence in patients with schizophrenia
por: Joe, Soohyun, et al.
Publicado: (2016)

PM395. The Effectiveness of Cross-Tapering Switching to Ziprasidone in Patients with Schizophrenia or Schizoaffective Disorder
por: Na, Kyoungsae, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_4qboshnn9p3j6il458q13s2fvm